Trial Profile
A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age (Protocol No. P05574/PN158)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary) ; Mometasone/formoterol (Primary) ; Montelukast (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Organon
- 14 Nov 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Nov 2012 Planned number of patients changed from 145 to 162 as reported by European Clinical Trials Database.
- 29 Oct 2012 Planned initiation date changed from 1 Nov 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.